Information Provided By:
Fly News Breaks for April 6, 2015
CYTX
Apr 6, 2015 | 11:31 EDT
Roth Capital said Cytori and partner Lorem Vascular Chinese FDA approval of Celution is a major win. The firm said the approval should move the needle "signficantly" for Celution and views current valuation for Cytori as attractive. Shares are Buy rated with a $6 price target.
News For CYTX From the Last 2 Days
There are no results for your query CYTX